Valneva (NASDAQ:VALN) Sets New 52-Week High - What's Next?

Key Points

• Valneva's stock reached a new 12-month high of $8.79, following a trading volume of 39,793 shares on Friday, compared to a previous close of $8.25.
• Analysts have mixed predictions, with Guggenheim reducing their price target from $15.00 to $14.00, while HC Wainwright maintained a $17.00 target and a "buy" rating.
• The company reported earnings per share of ($0.13), exceeding expectations significantly, along with quarterly revenue of $51.79 million, above analyst estimates of $41.80 million.

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s stock price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $8.79 and last traded at $8.74, with a volume of 39793 shares traded. The stock had previously closed at $8.25.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Guggenheim cut their target price on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Valneva in a research report on Tuesday, April 15th.

Valneva Trading Up 8.3%

The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.92. The stock has a 50 day simple moving average of $6.51 and a 200-day simple moving average of $6.62. The firm has a market cap of $783.25 million, a P/E ratio of -7.74 and a beta of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.11. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. On average, equities research analysts expect that Valneva SE Sponsored ADR will post 0.13 EPS for the current fiscal year.

Institutional Trading of Valneva

An institutional investor recently bought a new position in Valneva stock. GAMMA Investing LLC acquired a new position in Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 13,964 shares of the company's stock, valued at approximately $94,000. 11.39% of the stock is owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.